5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Market is Segmented by Type of Technology, Application (Bone Graft Substitutes, Osteoarticular Diseases, Dermatology, Cardiovascular, Central Nervous System, and Other Applications), and Geography
The key factors propelling the growth of the regenerative medicines market are the increasing adoption of stem-cell technologies, gene therapies, and tissue engineering, and the technological advancements in regenerative medicines.
Stem-cell technology is a rapidly developing technology that plays a major role in regenerative medicines, as it also serves the disciplines of tissue engineering, developmental cell biology, cellular therapeutics, gene therapy, chemical biology, and nanotechnology. The applications of stem-cell technologies in the treatment of diseases have ultimately increased the overall adoption rate of these technologies across the world.
The market is experiencing major technological advancements in biologics, biomaterials, stem-cell technology, and tissue engineering, thereby, contributing to its growth. There have also been various recent advancements in regenerative medicines, including regenerated tracheas for transplant, 3D bioprinting, stem-cell treatments for vision loss, and stem-cell treatments for heart repair.
The current market is also witnessing extensive R&D activities. Apart from R&D activities being conducted by the private players, there is a significant involvement of the academic institutions, for conducting various research processes. Therefore, in the future, several new biotech and medtech companies are expected to come up, as the result of the current R&D endeavors across the world.
As per the scope of this report, regenerative medicines are used to repair, replace, and regenerate the tissues and organs affected by injury, disease, or the natural aging process. These medicines restore the functionality of cells and tissues and are used in several degenerative disorders, such as dermatology, neurodegenerative diseases, cardiovascular, and orthopedic applications.
|By Type of Technology|
|Stem Cell Therapy|
|Other Types of Technologies|
|Bone Graft Substitutes|
|Central Nervous System|
Report scope can be customized per your requirements. Click here.
Cardiac stem-cell therapy has a great potential to prompt myocardial regeneration in patients with ischemic heart disease. The selection of the most suitable cell type is pivotal for its successful application. Various cell types, including crude bone marrow mononuclear cells, skeletal myoblast, and hematopoietic and endothelial progenitors, have already advanced into the clinical arena, based on promising results from different experimental and preclinical studies. Different next-generation cell types are also under investigation, for the treatment of diseased myocardium.
As per the European Cardiovascular Disease's 2017 statistics, published by the European Heart Network, over the past two decades, the absolute number of CVD cases has increased in Europe, with increases in the number of new CVD cases found in most countries. In 1990, the incidence of CVD was approximately 4.7 million and this number has increased to more than 5.4 million by 2015. As the incidence of CVD increases in Europe, the demand for cardiac regenerative techniques in applications like cardiac stem (CSCs) and progenitor cells (CPCs) are also expected to increase. This is expected to help the market to grow in the future.
To understand key trends, Download Sample Report
The European market is competitive, due to the presence of almost all the global players. Many of these global players have their headquarters in the European countries, which increases the accessibility of regenerative medicines throughout the continent.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Adoption of Stem-cell Technology
4.2.2 Technological Advancements in Regenerative Medicines
4.3 Market Restraints
4.3.1 Regulatory and Ethical Issues
4.3.2 High Cost of Treatments
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Type of Technology
5.1.1 Stem Cell Therapy
5.1.3 Tissue Engineering
5.1.4 Other Types of Technologies
5.2 By Application
5.2.1 Bone Graft Substitutes
5.2.2 Osteoarticular Diseases
5.2.5 Central Nervous System
5.2.6 Other Applications
5.3 By Geography
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allergan PLC
6.1.2 Smith & Nephew (Osiris Therapeutics)
6.1.3 Integra Lifesciences Corporation
6.1.4 Cook Biotech Incorporated
6.1.5 Baxter International Inc.
6.1.6 Medtronic PLC
6.1.7 Thermo Fisher Scientific
6.1.8 Sigma Aldrich (a Subsidiary of Merck KGaA)
6.1.9 Becton Dickinson and Company
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments